Recently, "Create Excellence in China with Ameile - 2nd CSCO Hansoh Pharma Lung Cancer Precision Diagnosis and Treatment Forum" was held simultaneously in Shanghai, Beijing and Guangzhou. Academician Yu Jinming of the Chinese Academy of Engineering and Professor Wu Yilong of Guangdong Provincial People's Hospital, as chairmen of the forum, discussed with participating experts on the exploration and innovation in lung cancer diagnosis and treatment. They once again spoke highly of Ameile (Almonertinib Mesilate Tablets), saying that it brings new hope for life to patients. Only innovators can go steady and far. Lyu Aifeng, President of Hansoh Pharma, said in his speech that technological innovation is always the key internal driving force and core competitiveness of Hansoh Pharma for high-quality and rapid development. After more than 20 years of innovation and exploration, Hansoh Pharma has built a proven R&D system and innovation platform. In the future, Hansoh Pharma will continue to uphold the innovation spirit, develop more innovative drugs, and work hand in hand with experts to contribute to the development of oncology in China. 

01.Technology-based Neဣw Cho♉ice of Precision Treatment

 Ameile is China's first original third-generation EGFR-TKI innovative drug independently developed by Hansoh Pharma, and also the world's first third-generation EGFR-TKI with median progression-free survival (MPFS) exceeding one year (second-line use). Over the year since its launch, Ameile has been widely used in clinical practice and won unanimous praise for its excellent clinical effects and study results. Academician Yu Jinming, chairman of the forum, pointed out in his speech that up to now, the study on NSCLC has delivered many exciting results. From a global perspective, China's independently developed drugs, study and data are increasingly visible in the world stage. We should firmly support Chinese pharmaceutical companies and help them grow bigger and stronger. With the continuous innovation of new therapies such as targeted therapy and immunotherapy, lung cancer has gradually moved towards "chronic disease" management. The available clinical data fully demonstrate that Ameile has excellent efficacy and safety. Professor Lu Shun, chairman of the Lung Cancer Committee of China Anti-Cancer Association and director of the Oncology Department of the Chest Hospital Affiliated to Shanghai Jiaotong University, and many other experts attending the forum said that Ameile can effectively improve patients' quality of life and bring more survival benefits and better treatment options for patients with advanced lung cancer. 

▲Ameile (Almonertinib Mesilate Tablets)

At the forum, the real cases shared by experts show that Ameile can effectively control brain metastasis lesions and has superior efficacy on brain metastasis population. It is worth noting that in February 2021, the Phase III study on first-line treatment of EGFR mutation-positive locally advanced or metastatic NSCLC has reached the primary study endpoint. Ameile will bring benefits to more lung cancer patients and provide more hope for survival. The latest study results will be released at ASCO 2021, which is worth looking forward to. 

02.Targeted Therapy Higher Drug Safety

 As China's first original third-generation EGFR-TKI drug, Ameile has not only remarkable therapeutic effects, but also a good safety profile. In the process of targeted therapy for NSCLC, patients often experience adverse reactions such as diarrhea and rash, especially interstitial pneumonia, which can seriously damage patients' quality of life and affect their compliance with the treatment regimen. Clinical data show that Ameile has low incidence of adverse reactions, good tolerance and a high safety profile, enhancing patient survival while effectively improving patients' quality of life. A real case where the switch to Ameile has brought benefits to a patient with interstitial pneumonia was also shared at the forum. Ameile's unique structural design optimization reduces the common adverse reactions of existing EGFR-TKI, and delivers excellent real-world safety performance.  

03.On the Way Towards Same Goal More Patients Benefit from Chinese Innovations

 The value of drugs is ultimately reflected in the benefit to patients. In December 2020, Ameile was included in the National Reimbursement Drug List, which not only protects the lives of lung cancer patients, but also relieves the financial burden on them. As the drug becomes affordable and accessible, more patients can benefit from medicine innovations in China. Recently, for the convenience of patients, the National Healthcare Security Administration (NHSA) has organized experts to select the first batch of 19 drugs with urgent clinical needs and low substitutability from the new negotiated drugs in 2020. Ameile is one of the first batch for its excellent efficacy and safety, and the list of medical institutions where Ameile is available can be queried on the NHSA platform. This will further improve the drug accessibility of Ameile, and allow more patients to receive timely and standardized drug treatment and obtain better treatment results, thus reducing the burden on the country and society to a certain extent. In the future, Hansoh Pharma will integrate superior resources, focus on innovation breakthroughs in the treatment of major diseases, promote transformation and upgrading through technological innovation, create excellence in pharmaceuticals and enhance innovation in China, so as to continue to meet the unmet medical needs in clinical practice, contribute to the treatment of tumor diseases and the development of medicine, and help facilitate the vigorous development of China's healthcare cause.